— News and commentary from the world of gastroenterology and hepatology The number of drug-induced liver injury (DILI) cases in the U.S. attributable to herbal and dietary supplements and cancer drugs has grown over the past two decades as DILI cases…
An estimated 60 million to 70 million Americans suffer from digestive diseases. Recent research suggests that PFAS can make matters worse. PFAS pollute waterways and accumulate in the fish swimming there. Your seafood, food wrappers, drinking water and skillets all likely contain…
Current European and UK guidance incorporates comorbidity assessment and, where appropriate, communication between dermatology and gastroenterology into treatment planning Plaque Psoriasis and Crohn’s Disease: Shared Biology, the IL-12/23 Pathway and Clinical Considerations Current European and UK guidance incorporates comorbidity assessment…
The story is only half the picture See behind the headlines See the data moving US, ASX and crypto markets right now. AbbVie (NYSE:ABBV) reported a 40.5% endoscopic remission rate at Week 24 for investigational ABBV-466 in its 300-patient Phase 2a TARGET-CD…
In a study published online July 25 in the journal Nature, University of California San Diego School of Medicine researchers identified a signaling pathway that activates the NLRP3 inflammasome implicated in several severe chronic inflammatory disorders. Newly Identified Target May Help with…
NASHVILLE, Tenn. — An allergen-specific, immune signature-directed diet led to significant improvements in patients with eosinophilic esophagitis compared with a sham elimination diet, according to results of a small, randomized study. Dietary elimination is often recommended for patients with eosinophilic esophagitis,…
RESEARCHERS have found that anti-CD20 treatment in multiple sclerosis (MS) has been associated with a higher risk of inflammatory bowel disease (IBD) than other modern disease-modifying therapy (DMT) options, according to a new Swedish population-based cohort study. Anti-CD20 biologics have…
In VIVID-1, one in five (20.4%) Omvoh-treated patients with Crohn's disease achieved corticosteroid-free deep remission, a composite outcome defined by simultaneous clinical remission, endoscopic remission and no corticosteroid use Comprehensive disease control was evaluated in a post hoc analysis at one year…
“Finding these patterns so early points to the potential of antibody profiling to support earlier risk detection, distinguish between disease subtypes and help identify patients who may benefit from more intensive therapy as early as possible,” he added. For the…
A new review of primary biliary cholangitis (PBC) has highlighted how interactions between immune cells and bile duct cells drive chronic inflammation, potentially leading to more personalised treatments. PBC is a chronic autoimmune disease that destroys small bile ducts inside…
Inflammatory bowel disease: Crohn's disease and ulcerative colitis, new biologic and oral drugs, surgery, diet and living with IBD.
An article joins this feed when it matches these terms. Each one is also a search of its own.